EP Patent

EP2826466A1 — Therapeutic compositions comprising rilpivirin hcl and tenofovir disoproxil fumarate

Assigned to Janssen Sciences Ireland ULC · Expires 2015-01-21 · 11y expired

What this patent protects

The invention provides multilayer tablets that contain Rilpivirine HCl, Emtracitabine, and Tenofivir DF. The tablets are useful for the treatment of HIV.

USPTO Abstract

The invention provides multilayer tablets that contain Rilpivirine HCl, Emtracitabine, and Tenofivir DF. The tablets are useful for the treatment of HIV.

Drugs covered by this patent

Patent Metadata

Patent number
EP2826466A1
Jurisdiction
EP
Classification
—
Expires
2015-01-21
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Sciences Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.